Inhibitor Therapeutics Inc (INTI)
Inhibitor Therapeutics Inc. (OTC Markets: INTI) is a healthcare company focused on pharmaceutical development. The company works on therapies aimed at patients with certain cancers and non-cancerous proliferation disorders in the United States, with a particular emphasis on prostate and lung cancer programs using itraconazole. Its clinical work has included a positive Phase 2b trial of SUBA-Itraconazole for basal cell carcinoma nevus syndrome. The company was previously known as HedgePath Pharmaceuticals, Inc. and adopted its current name in August 2019. Founded in 1992, Inhibitor Therapeutics is based in Tampa, Florida.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-INTI
|
$0.045
|
-24.2% Downside
|
Overvalued
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 10, 2026
|
10.254 M
|
14.982 M
|
0.3%
|
45.0%
|
-138.4
|
97.4%
|
